Quick Answer
INTERPACE BIOSCIENCES, INC. reported Cash and Equivalents of $2.50 million for fiscal year 2025.
INTERPACE BIOSCIENCES, INC. Cash and Equivalents — Annual History
| Fiscal Year | Cash and Equivalents | YoY Change |
|---|---|---|
| 2025 | $2.50M | +71.5% |
| 2024 | $1.46M | -30.9% |
| 2024 | $2.11M | +4.7% |
| 2024 | $2.02M | -28.2% |
| 2024 | $2.81M | -19.6% |
| 2023 | $3.50M | -31.1% |
| 2023 | $5.08M | -9.2% |
| 2023 | $5.60M | +15.9% |
| 2022 | $4.83M | +80.7% |
| 2021 | $2.67M | -3.6% |
| 2020 | $2.77M | +19.4% |
| 2019 | $2.32M | -61.8% |
| 2018 | $6.07M | -60.1% |
| 2017 | $15.20M | +2424.8% |
| 2016 | $602.0K | -92.8% |
| 2015 | $8.31M | -64.0% |
| 2014 | $23.11M | -49.4% |
| 2013 | $45.64M | -13.5% |
| 2012 | $52.78M | -18.0% |
| 2011 | $64.34M | +2.6% |
| 2010 | $62.71M | -13.5% |
| 2009 | $72.46M | — |
Quarterly Cash and Equivalents
| Quarter Ending | Cash and Equivalents | YoY | QoQ |
|---|---|---|---|
| October 31, 2025 | $2.10M | — | +47.6% |
| September 30, 2025 | $1.42M | +1.6% | +183.5% |
| June 30, 2025 | $502.0K | +0.4% | -58.0% |
| March 31, 2025 | $1.20M | -57.5% | -18.1% |
| December 31, 2024 | $1.46M | -58.2% | +4.4% |
| September 30, 2024 | $1.40M | -72.2% | +180.0% |
| June 30, 2024 | $500.0K | -90.2% | -82.2% |
| March 31, 2024 | $2.81M | -49.7% | -19.6% |
- INTERPACE BIOSCIENCES, INC. showed an increase of +71.5% in Cash and Equivalents compared to the prior fiscal year.
- Over the 2009–2025 period, INTERPACE BIOSCIENCES, INC.’s cash and equivalents has declined by 96.5% (from $72.46 million to $2.50 million).
- The most recent figure is from INTERPACE BIOSCIENCES, INC.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 30, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: